ArticleJournal of magnetic resonance imaging : JMRI2026
Thalamic Nuclei Atrophy in Type 1 Diabetes Mellitus Across Disease Duration.
Article in Journal of magnetic resonance imaging : JMRI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThalamic volume loss is one of the most consistent neuroimaging findings in type 1 diabetes mellitus (T1DM). However, the thalamus comprises multiple nuclei with distinct functions, and whether specific nuclei show differential vulnerability remains unclear. PURPOSE: To investigate the characteristics of intra-thalamic nuclear atrophy in T1DM and evaluate its association with disease duration. FIELD STRENGTH/SEQUENCE: 3.0 T/T1-weighted magnetization-prepared-rapid-acquisition-of-gradient-echo (MPRAGE). STUDY TYPE: Prospective. POPULATION: Forty-two subjects with T1DM (18-68 years, 17 males/25 females) and 39 healthy controls (18-69 years, 16 males/23 females). ASSESSMENT: Multi-atlas-based segmentation was used to quantify volumes of 20 thalamic nuclei. Additionally, volumes of anatomical and functional subregions were derived based on topographic and functional nuclear classifications. STATISTICAL TESTS: Group differences were assessed using general linear models. Associations between thalamic volume loss and disease duration were evaluated via partial correlations and exponential regression models to estimate duration-related atrophy rates. p value < 0.05 was considered significant.
resultsParticipants with T1DM showed significant bilateral reductions in total thalamic volume (left: 7.6%, Cohen's d = 0.91; right: 8.0%, Cohen's d = 0.95). The most pronounced atrophy was observed in the anterior, medial, and lateral thalamic subregions, with volume reductions of 15.8%, 8.6%, and 7.3%, respectively, particularly in cognition- and motor-related nuclei (9.4% and 9.2%, respectively). Longer disease duration was significantly associated with smaller thalamic volumes in the bilateral whole thalamus (r DATA
conclusionT1DM is associated with spatially heterogeneous atrophy of thalamic nuclei, with preferential involvement of the anterior, medial, and lateral subregions. Disease duration seems to accelerate neurodegenerative changes. EVIDENCE LEVEL: 2. TECHNICAL EFFICACY: Stage 2.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.